Russia approves trials of combined AstraZeneca/Sputnik V vaccine

A view shows the Kremlin amid the coronavirus disease (COVID-19) outbreak in Moscow, Russia April 20, 2020. REUTERS/Maxim Shemetov/File Photo

MOSCOW, July 26 (Reuters) - Russia has given the green light for clinical trials combining a British shot from AstraZeneca Plc (AZN.L) and Oxford University with Russia's Sputnik V vaccine to go ahead, according to Russia's state drug register.

The health ministry's ethical committee had in May suspended the approval process for the clinical trials, and requested additional information. read more

According to the state drug register, five Russian clinics will hold trials that are set to finish in early March, 2022.

Register now for FREE unlimited access to

Both the AstraZeneca/Oxford and Sputnik V vaccines involve two doses - an initial shot and a booster - but Sputnik V uses different viral vectors for its two shots.

Russian Direct Investment Fund (RDIF), which promotes the use of the Sputnik V vaccine, has welcomed the decision to go ahead with the trials.

"Currently, RDIF is conducting joint clinical trials to combine the first component of Sputnik V - the Sputnik Light vaccine - with vaccines from other foreign manufacturers," it said in a statement.

"In particular, the Sputnik Light vaccine can be used in combination with other vaccine to increase their effectiveness including against new variants appearing as a result of the mutation of the virus."

So-called viral vector shots use harmless modified viruses as vehicles, or vectors, to carry genetic information that helps the body build immunity against future infections.

Human trials of a COVID-19 vaccine combining the AstraZeneca/Oxford shot with Sputnik V had already been approved in Azerbaijan, the United Arab Emirates, Belarus and Argentina.

Register now for FREE unlimited access to
Reporting by Polina Nikolskaya and Vladimir Soldatkin; Editing by Timothy Heritage and Grant McCool

Our Standards: The Thomson Reuters Trust Principles.